2 552

Cited 93 times in

Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin

DC Field Value Language
dc.contributor.author김평환-
dc.contributor.author손주혁-
dc.contributor.author최정우-
dc.date.accessioned2014-12-20T17:18:22Z-
dc.date.available2014-12-20T17:18:22Z-
dc.date.issued2011-
dc.identifier.issn0142-9612-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/94349-
dc.description.abstractPEGylation of adenovirus (Ad) increases plasma retention and reduces immunogenicity, but decreases the accessibility of virus particles to target cells. We tested whether PEGylated Ad conjugated to Herceptin (Ad-PEG-HER) can be used to treat Her2/neu-positive cells in vitro and in vivo to demonstrate the therapeutic feasibility of this Ad formulation. Ad-PEG-HER transduced Her2/neu-overexpressing cancer cells through a specific interaction between Herceptin and Her2/neu. Ad-PEG-HER treatment resulted in higher plasma retention and lower neutralizing antibody and IL-6 production than naked Ad. This formulation was extended to generate a Her2/neu-targeted, PEGylated oncolytic Ad (DWP418-PEG-HER). DWP418-PEG-HER specifically killed Her2/neu-positive cells and performed better than non-targeted and naked Ad in vivo. DWP418-PEG-HER showed a 10(10)-fold increase in the liver to tumor biodistribution compared with naked Ad. Immunohistochemical staining confirmed accumulation of Ad E1A in tumors. These data suggest that targeted gene therapy with the PEGylated Ad conjugated with Herceptin might shed a light on its therapeutic application for metastatic cancer in the future.-
dc.description.statementOfResponsibilityopen-
dc.format.extent2314~2326-
dc.relation.isPartOfBIOMATERIALS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenoviridae/drug effects-
dc.subject.MESHAdenoviridae/metabolism*-
dc.subject.MESHAnimals-
dc.subject.MESHAntibodies, Monoclonal/adverse effects*-
dc.subject.MESHAntibodies, Monoclonal/pharmacokinetics-
dc.subject.MESHAntibodies, Monoclonal/pharmacology*-
dc.subject.MESHAntibodies, Monoclonal/toxicity-
dc.subject.MESHAntibodies, Monoclonal, Humanized-
dc.subject.MESHAntineoplastic Agents/pharmacology-
dc.subject.MESHCell Death/drug effects-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHDrug Delivery Systems/methods*-
dc.subject.MESHHumans-
dc.subject.MESHImmunity, Humoral/drug effects-
dc.subject.MESHImmunity, Innate/drug effects-
dc.subject.MESHInjections, Intravenous-
dc.subject.MESHLiver/drug effects-
dc.subject.MESHLiver/pathology-
dc.subject.MESHMice-
dc.subject.MESHOncolytic Viruses/drug effects-
dc.subject.MESHOncolytic Viruses/metabolism-
dc.subject.MESHPolyethylene Glycols/chemistry*-
dc.subject.MESHReceptor, ErbB-2/metabolism-
dc.subject.MESHTissue Distribution/drug effects-
dc.subject.MESHTransduction, Genetic-
dc.subject.MESHTrastuzumab-
dc.subject.MESHXenograft Model Antitumor Assays-
dc.titleActive targeting and safety profile of PEG-modified adenovirus conjugated with herceptin-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentMedical Research Center (임상의학연구센터)-
dc.contributor.googleauthorPyung-Hwan Kim-
dc.contributor.googleauthorJoo-Hyuk Sohn-
dc.contributor.googleauthorJoung-Woo Choi-
dc.contributor.googleauthorYukyung Jung-
dc.contributor.googleauthorSung Wan Kim-
dc.contributor.googleauthorSeungjoo Haam-
dc.contributor.googleauthorChae-Ok Yun-
dc.identifier.doi10.1016/j.biomaterials.2010.10.031-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01088-
dc.contributor.localIdA01995-
dc.contributor.localIdA04179-
dc.relation.journalcodeJ00312-
dc.identifier.eissn1878-5905-
dc.identifier.pmid21227505-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0142961210013384-
dc.subject.keywordCancer gene therapy-
dc.subject.keywordAdenovirus-
dc.subject.keywordAd conjugated bioreducible polymer-
dc.subject.keywordHybrid vector-
dc.subject.keywordActive targeting-
dc.contributor.alternativeNameKim, Pyung Hwan-
dc.contributor.alternativeNameSohn, Joo Hyuk-
dc.contributor.alternativeNameChoi, Joung Woo-
dc.contributor.affiliatedAuthorKim, Pyung Hwan-
dc.contributor.affiliatedAuthorSohn, Joo Hyuk-
dc.contributor.affiliatedAuthorChoi, Joung Woo-
dc.rights.accessRightsnot free-
dc.citation.volume32-
dc.citation.number9-
dc.citation.startPage2314-
dc.citation.endPage2326-
dc.identifier.bibliographicCitationBIOMATERIALS, Vol.32(9) : 2314-2326, 2011-
dc.identifier.rimsid27563-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.